KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biolife Solutions (BLFS) Tax Provisions (2019 - 2025)

Biolife Solutions (BLFS) has disclosed Tax Provisions for 7 consecutive years, with -$151000.0 as the latest value for Q4 2025.

  • Quarterly Tax Provisions fell 729.17% to -$151000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $71000.0 through Dec 2025, up 286.84% year-over-year, with the annual reading at $49000.0 for FY2025, 228.95% up from the prior year.
  • Tax Provisions for Q4 2025 was -$151000.0 at Biolife Solutions, down from $82000.0 in the prior quarter.
  • The five-year high for Tax Provisions was $126000.0 in Q2 2025, with the low at -$12.6 million in Q2 2021.
  • Average Tax Provisions over 5 years is -$1.3 million, with a median of -$80000.0 recorded in 2024.
  • The sharpest move saw Tax Provisions tumbled 7912.12% in 2021, then soared 12500.0% in 2025.
  • Over 5 years, Tax Provisions stood at -$2.6 million in 2021, then surged by 88.4% to -$299000.0 in 2022, then increased by 8.7% to -$273000.0 in 2023, then skyrocketed by 108.79% to $24000.0 in 2024, then plummeted by 729.17% to -$151000.0 in 2025.
  • According to Business Quant data, Tax Provisions over the past three periods came in at -$151000.0, $82000.0, and $126000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.